Study of the Orsiro Drug Eluting Stent System
- Target Lesion Failure (TLF) comparable to Xience Prime* although separating over time in favor of Orsiro out to 48 months
- Absence of definite or probable stent thrombosis also in high risk populations such as diabetic and small vessel subgroup out to 48 months
- The results of this prospective, randomized study confirms the safety and efficacy of Orsiro
© BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.
*Xience and Xience Prime are registered trademarks of Abbott Cardiovascular Systems.
Reference: Ton Slagboom on behalf of the BIOFLOW-II Investigators, Poster, euroPCR 2017